NO20072658L - Nye anvendelser av ostrogen beta agonister - Google Patents

Nye anvendelser av ostrogen beta agonister

Info

Publication number
NO20072658L
NO20072658L NO20072658A NO20072658A NO20072658L NO 20072658 L NO20072658 L NO 20072658L NO 20072658 A NO20072658 A NO 20072658A NO 20072658 A NO20072658 A NO 20072658A NO 20072658 L NO20072658 L NO 20072658L
Authority
NO
Norway
Prior art keywords
new uses
beta agonists
estrogen beta
estrogen
agonists
Prior art date
Application number
NO20072658A
Other languages
English (en)
Inventor
Heather Anne Harris
Mark Day
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20072658L publication Critical patent/NO20072658L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer metoder for behandling av kognitive sykdommer eller lidelser og symptomer derav med østrogen beta-selektive agonister.
NO20072658A 2004-12-17 2007-05-24 Nye anvendelser av ostrogen beta agonister NO20072658L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17
PCT/US2005/045375 WO2006065968A2 (en) 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases

Publications (1)

Publication Number Publication Date
NO20072658L true NO20072658L (no) 2007-09-12

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072658A NO20072658L (no) 2004-12-17 2007-05-24 Nye anvendelser av ostrogen beta agonister

Country Status (20)

Country Link
US (1) US20060135574A1 (no)
EP (1) EP1824478A2 (no)
JP (1) JP2008524236A (no)
KR (1) KR20070086329A (no)
CN (1) CN101321524A (no)
AR (1) AR051844A1 (no)
AU (1) AU2005316561A1 (no)
BR (1) BRPI0519111A2 (no)
CA (1) CA2590258A1 (no)
GT (1) GT200500370A (no)
IL (1) IL183604A0 (no)
MX (1) MX2007007347A (no)
NI (1) NI200700152A (no)
NO (1) NO20072658L (no)
PA (1) PA8656601A1 (no)
PE (1) PE20061113A1 (no)
RU (1) RU2007120254A (no)
TW (1) TW200637545A (no)
WO (1) WO2006065968A2 (no)
ZA (1) ZA200705103B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
CA2959753A1 (en) * 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
AU2018243482B2 (en) * 2017-03-30 2022-04-21 Concordia University, Inc. Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
CA2370126A1 (en) * 1999-04-16 2000-10-26 Timothy Martin Piser Estrogen receptor-.beta. ligands
AU2002221239A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
EP1345914A1 (en) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
EP1310799B1 (en) * 2001-11-07 2005-12-21 Schering AG In vitro screening for ligands of the estrogen receptor
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
AU2003267241A1 (en) * 2002-09-19 2004-04-08 Merck And Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
WO2006007503A1 (en) * 2004-07-01 2006-01-19 Wyeth Tetracyclic compounds as estrogen ligands

Also Published As

Publication number Publication date
BRPI0519111A2 (pt) 2008-12-23
GT200500370A (es) 2006-07-13
WO2006065968A8 (en) 2008-09-12
AU2005316561A1 (en) 2006-06-22
CN101321524A (zh) 2008-12-10
ZA200705103B (en) 2009-11-25
EP1824478A2 (en) 2007-08-29
MX2007007347A (es) 2007-07-13
JP2008524236A (ja) 2008-07-10
NI200700152A (es) 2008-06-17
PA8656601A1 (es) 2006-12-07
AR051844A1 (es) 2007-02-14
CA2590258A1 (en) 2006-06-22
US20060135574A1 (en) 2006-06-22
WO2006065968A2 (en) 2006-06-22
KR20070086329A (ko) 2007-08-27
PE20061113A1 (es) 2006-11-06
IL183604A0 (en) 2007-10-31
TW200637545A (en) 2006-11-01
WO2006065968A3 (en) 2008-04-10
RU2007120254A (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
ECSP077315A (es) Proteínas de fusión de dominio de unión
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
EA201070127A1 (ru) Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
EA200901042A1 (ru) Производные 1-бензенсульфонил-1h-индола в качестве ингибиторов активности ccr9
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
NO20072658L (no) Nye anvendelser av ostrogen beta agonister
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
NO20082459L (no) Nye prosesser for fremstilling av piperazinyl og diazapanylbenzamidderivater
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
DE602006016953D1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application